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Abstract
Companies in the biotechnology industry face major challenges in developing and commercializing
new products. Focusing on publicly traded biotechnology firms that are not members of university
incubators or research parks, this paper argues that the links these companies develop with universities
can have beneficial effects on a company’s operations. Analysis of 2457 alliances undertaken by 147
biotechnology firms shows that companies with university linkages have lower research and
development (R&D) expenses while having higher levels of innovative output. However, the results do
not support the proposition that companies with university linkages achieve higher financial
performance than similar firms without such linkages.
D 2002 Elsevier Science Inc. All rights reserved.
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1. Introduction
Companies that compete in high-technology industries face major challenges in their quest
for survival and profitability (Oliver and Liebeskind, 1998). In these industries, the
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competitive landscape and the rules of competitive rivalry change constantly (D’Aveni,
1994), requiring firms to develop their absorptive capacity and the ability to continually
reconfigure their competencies for value creation (Zahra and George, 2000). While
opportunities for profitability and growth abound in these dynamic industries, the risks of
failure are also high. Industries, such as biotechnology have been witness to some of the
most gallant competitive efforts that nonetheless have ended in organizational defeat (Grant,
1998). To survive and achieve profitability, these companies need to act entrepreneurially to
assemble and use their resources in ways that give them a competitive advantage (Barney
1991).
Companies in science-based industries, however, encounter serious challenges in gaining
access to the resources needed to build strong capabilities (Zahra, 1996). Even though success
requires a firm to utilize diverse technological capabilities, accumulating these capabilities is
a time-consuming and an expensive process that is fraught with uncertainty (Teece et al.,
1997). Firms, therefore, need to develop beneficial relationships with the suppliers of these
scarce resources (Oliver and Liebeskind, 1998). These suppliers, in turn, are likely to respond
favorably to the firm’s needs if it is backed by a credible third party whom they trust (Pfeffer
and Nowak, 1976; Powell et al., 1996). Relationships with established and reputable
organizations such as leading research universities can enhance a company’s legitimacy in
the eyes of other powerful stakeholders (Mian, 1997). These relationships also give the firm
access to diverse resources, sometimes at prices lower than the going market rates, which
enables the firm to reduce its overall costs and achieve superior performance (Geisler, 1995;
Matkin, 1990).
A widely used strategy in science-based industries is for firms to develop close linkages
with universities (Bowie, 1994; Peters et al., 1998) that can give companies flexibility in
conducting research and development (R&D) (MacLachlan, 1995; Sage, 1996). This is
important because modern technology demands the mastery of multifaceted scientific
disciplines that only few companies possess. Established research universities employ
scientists who devote their time to conducting research in existing and emerging technologies.
Usually leaders in their fields, these researchers also benefit from their universities’ invest-
ments in R&D. Universities conduct about 60% of all basic research and a much smaller but
still significant amount of applied research in the US (Lewis, 1990, p. 193). University
research spending reached US$26.8 billion in 1999, up 10% over the previous year. With
12,324 invention discoveries reported in 1999 (up 5% over 1998) and the number of patents
filed at 5545 (up 15% over 1998), universities can be a valuable source of knowledge and
innovation (AUTM, 2000). In 1999 alone, 344 new ventures were formed from university-
based inventions (AUTM, 2000).
Linkages with universities give the firm a window on emerging technologies and scientific
discoveries (Lepkowski, 1996). University scientists typically view these links as providing
fertile grounds for developing and testing theories, honing their skills, and training and
placing their students (Cyert and Goodman, 1997). Links with business firms can also
generate the funds needed to pursue important R&D projects and improve the quality of a
university’s research and teaching (Lee, 1996; Webster, 1994). Business–university alliances,
therefore, can be a ‘‘win–win’’ situation, where the objectives of the firm and the university
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are achieved (Bolton, 1995; Bowie, 1994). A National Science Foundation report (NSF,
1998) concludes that there is an increasing trend in cooperation between universities and
industry in basic research. This interaction becomes explicit with shared research agendas,
industry research funding, and joint authorship on research papers that appear in the public
research domain. For example, between 1990 and 1997, MIT faculty and graduates have
founded more than 60 companies that have a combined market value of US$2.5 billion and
created more than 2000 high-technology jobs. MIT, which receives about 100 patents each
year, is illustrative of a positive trend in university–business relationships (Thayer, 1997). In
order to tap the intellectual potential of its scientific community, universities such as the
University of Wisconsin-Madison invest nearly US$500 million in research every year and
have built their own research parks. Wisconsin’s research park offers 23 buildings with more
than 800,000 ft2 of facility space.
Other research universities, such as Georgia Tech (Blau, 1999), Chicago (Melcher, 1998),
Cornell (Thayer, 1997), Texas at Austin (Smilor et al., 1990), and Stanford (Thuemer, 1997)
have entered into partnerships with businesses. These collaborations have been spurred by the
active participation of the NSF (1998), through its Industry–University Cooperative Research
Program. As of 1998, there were 18 such centers in the US, encompassing 700 partnerships
with 550 companies (Hairston et al., 1998). Universities outside the US have also worked
closely to foster the growth of science and technology-based new ventures (for a review, see
Blau, 1999; Carayannis et al., 1998; Meyer-Krahmer and Schmoch, 1998).
In this article, we examine the potential effects of linkages with a university on firm
innovation and performance outcomes among publicly traded biotechnology companies. The
industry represents an important scientific paradigm shift that promises to alter the way
science and its applications are made (Zahra and George, 1999). Universities have also played
a key role in giving birth to this industry and supporting the creation of new companies to
exploit its discoveries (Kuhlman, 1996). This has made the biotechnology industry an ideal
setting to study collaborative relationships (Oliver and Liebeskind, 1998). Yet, little empirical
research documents the positive effects of university linkages on firm innovation and
performance.
As with other emerging industries, the biotechnology industry contains a wide range of
organizations that vary in their ownership and missions (Zucker et al., 1998). This suggests
that those biotechnology firms that seek linkages with universities are likely to emphasize
different goals and priorities and exhibit different management styles in dealing with
university researchers and scientists. Therefore, it should be noted that our analyses focus
primarily on one, but crucial segment of the biotechnology industry: publicly traded firms.
The study excludes firms that are privately held or lodged in university-based technology
incubators (UBTIs) or research parks. Given that these firms may have access to different
resources, generalizations of our results should be made with caution.
Section 2 reviews the literature on university–business alliances and presents the study’s
hypotheses on the differences in the innovative output and financial performance of
biotechnology firms with linkages vs. without linkages to universities. This is followed by
Section 3, a section on methodology and empirical analysis to test the hypotheses. Section 6
reviews the results and discusses their practical and theoretical implications.
G. George et al. / Journal of Business Venturing 17 (2002) 577–609 579
2. Theoretical background and hypotheses
Understanding the linkages between universities and biotechnology firms requires an
appreciation of the benefits and shortcomings of these relationships. A limitation of past
research in this area is the absence of a unifying framework that clarifies the antecedents and
consequences of these alliances (Mian, 1997). This has led researchers to follow different
theoretical frameworks, generating contradictory and fragmented findings. Even though this
research has been criticized as being descriptive and lacking in theory (Dahlstrand, 1997), we
can gain some insights into the factors that may influence the outcomes biotechnology
companies gain from joining alliances with universities. The literature on UBTIs and
university–business alliances has addressed these issues and is, therefore, reviewed next.
2.1. University-based technology incubators
Collaborative relationships between US universities and industry are nearly a century old
(Blumenthal, 1994; Bowie, 1994), reflecting the mutual needs of the two communities to join
forces to achieve complex but varied goals (Bolton, 1995; Brannock and Denny, 1998;
Cukor, 1992; Merrifield, 1987). These relationships are expected to increase because of the
declining federal and state support for R&D in the US, the growing complexity of technology,
and the ever-rising speed of technological change. These factors appear to underlie university
faculties’ growing acceptance of collaborative relationships with industry, as revealed by the
results of a survey of 1000 faculty members (Lee, 1996). While the goals, nature, and
structure of these collaborations differ (Nimtz et al., 1995), there is some anecdotal evidence
that both universities and business firms can benefit from these relationships (Bowie, 1994;
Brannock and Denny, 1998). The remainder of this section reviews the benefits publicly
traded biotechnology firms can gain from their linkages with universities.
Oliver and Libeskind (1998) suggest that the birth and growth of the biotechnology
industry have been made possible by the close, collaborative relationships between
universities and business companies. The founders of many of these young companies have
been professors and researchers, which have facilitated communication between managers
and universities. New biotechnology firms have also found support from the incubators
universities have established to capitalize on the growth of this industry. These incubators
have had the support of public policymakers who are eager to attract and retain entrepre-
neurial companies in their home states. In Georgia, for example, there are a dozen such
incubators, including a biotechnology incubator sponsored by Georgia Tech and Emory
University.
Apart from biotech, UBTIs have been used in different industries as well. In fact, Mian
(1997) suggests that there are over 50 such UBTIs in the US. Given their potential
importance, UBTIs have received some attention in prior research (Merrifield, 1987; Udell,
1990). However, most past research on UBTIs is descriptive or anecdotal in nature (e.g.,
Bolton, 1995; Mian, 1997; Udell, 1990). Furthermore, few studies have documented the
effect of UBTIs on firm performance (Mian, 1997). Consequently, credible evidence on the
contributions of UBTIs is difficult to locate.
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In one of the first published authoritative studies, Roberts (1968) examined the spin-offs and
potential benefits of ties with universities, especially MIT. Roberts concluded that universities
foster the creation of technology-based new ventures. Dorfman (1983), who studied the
development of high-technology companies in the Boston area, concluded that MIT was the
main contributing factor. Dorfman also found that the second most important factor was the
presence of other high-technology firms, which is determined by the presence of research-
oriented universities (Dahlstrand, 1997). Allen (1985), who examined 45 UBTIs, documented
the different services these organizations offered their members. These varied services can
sustain and foster the growth of young entrepreneurial companies.Who studied 117 incubators,
concluded that UBTIs generate benefits, such as secretarial, administrative, counseling, and
other services, that facilitate the growth of high-technology ventures. Geisler et al. (1990)
studied 23 federally sponsored university–business centers and found that multiple factors
(founders, organization, and administration) interact to determine these centers’ success and net
contributions. Udell (1990), who studied 71 UBTI, provided a comprehensive list of the
services these organizations offered their members. These services can reduce the operating
costs of fledgling firms’ operations as they seek to establish their market positions.
Past UTBI research highlights several benefits that accrue to the business and university
communities (e.g., Carayannis et al., 1998; Geisler, 1995; Etzkowitz, 1998). These benefits
include job creation through new venture creation (Allen, 1985), wherein UBTIs can act as a
source of cheaper specialized labor in the form of graduate students (Gluckv et al., 1987) and
provide access to a steady stream of talented graduates and researchers (McGee, 1996; Smilor
et al., 1990). UBTIs also spur technology-based entrepreneurship and innovation (Abetti and
Stuart, 1985; Hisrich and Smilor, 1988; Mian, 1994). UBTIs, therefore, can act as a catalyst in
regional development by providing an opportunity for new ventures to contribute to the local
economy (Kuratko and LaFollette, 1987; Thayer, 1997). UBTIs also contribute to this goal
through localized knowledge spillovers from university interactions and clustering of firms
that generates a self-sustaining market for related services (Audretsch and Stephan, 1996;
Ceccagnoli et al., 1998; Zucker et al., 1998).
Two conclusions can be drawn from prior research on UBTIs. First, UBTIs offer young
companies several benefits that can nurture their growth and progress. Second, questions
remain about the extent of the services offered by the incubators (Udell, 1990; Mian, 1997).
While the present study does not look specifically into the role of UBTIs in improving a
firm’s performance, UBTIs are an example of positive outcomes some companies can gain by
developing linkages with universities (Kuratko and LaFollette, 1987; Mian, 1997). This
article explores the impact of university linkages (particularly alliances) on a firm’s
innovative outputs, though such firms do not necessarily belong to an UBTI.
Universities can contribute to the growth of an entrepreneurial culture in a region in other
important ways (Carayannis et al., 1998; Dahlstrand, 1997; Thayer, 1997). For examples,
some states (e.g., Georgia, Massachusetts, North Carolina, Virginia, and Wisconsin) have
attempted to promote the creation and growth of high-technology companies by creating
science parks that attract fledging companies and key service providers. There are over 140
such science parks in the US (Thuemer, 1997). Cabral and Dahab (1998), in their study of
biotechnology firms, have concluded that the presence of the strong research-oriented
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universities close to these parks is a key requirement for success. Prevezer (1997) also
suggests that the presence of strong research universities in a region is a major factor in
biotechnology companies’ location decision.
In spite of the positive outcomes, linkages between universities and business firms have
been criticized on several grounds. Business–industry partnerships can be problematic in
terms of quality control, coordination time, shared credit, and communication problems
(Jasso, 1996). Slaughter (1990) notes that business leaders deal in both cooperation and
cooptation with diverse institutions, and therefore may have multiple agendas when they form
partnerships with universities. Powers et al. (1988) also warn that these partnerships may
cause the faculty to spend less time working within their departments which in turn causes the
departments to be less productive and cohesive. Incompatibilities between cultures, such as
secrecy vs. free dissemination of knowledge, can be a stumbling block to university–industry
alliances (Bower, 1992). University scientists often have priorities that conflict with strict
industry schedules and may cause tension in collaborative activities (Bower, 1992; Eisenberg,
1996). Successful university–industry alliances can result in the formation of a university
company where researchers become entrepreneurs and conflicts of interest may develop
between their academic and corporate roles (Piercey, 1998). Close ties with the industry
might also pressure faculty to pursue projects with strong applied orientations and are of
immediate benefit to partner companies (Cukor, 1992), a practice which can weaken basic
research (Lee, 1996). These drawbacks aside, research on 25 universities in Europe and the
US over a 6-year period concluded that links with the universities are valued and important.
They provide a ready source of external advice and frequently result in access to unique
know-how and expertise (Blair and Hitchens, 1998).
The ever-growing number of linkages between business firms and universities highlights the
potentially beneficial impact of institutional links on a company’s performance (Geisler, 1995).
A firm can benefit from these links in their credibility, legitimacy, resources, and costs (Lewis,
1990). Despite the potential benefits of firm–university links, however, empirical documenta-
tion of their actual contributions is limited (Cyert and Goodman, 1997), and findings on this
issue have been inconsistent (Blair and Hitchens, 1998; Harmon et al., 1997). Past research
does not provide answers to simple questions such as: Do these links reduce a firm’s R&D
costs? Do they enhance the firm’s ability to innovate and improve a company’s performance?
To address these fundamental issues through a study of biotechnology firms, this paper
suggests that firm–university linkages can increase a company’s access to knowledge (e.g.,
scientific advances) and other key resources (e.g., market information). Linkages with
universities can also serve as a magnet that attracts technologically capable alliance partners
to collaborate with the firm, which can improve the firm’s knowledge base and its innovative
outputs (e.g., patents). These linkagesmay also reduce a firm’s costs, especially those relating to
knowledge creation (e.g., R&D). These innovative outputs and cost reductions can give a firm a
competitive advantage that can improve its financial performance (Grant, 1996). Currently, we
know very little about the costs vs. the benefits that firms achieve from establishing links with
universities, especially in their R&Doperations. Given the expected growth of these alliances in
the biotechnology industry, this study aims to fill this gap in the literature by exploring the effect
of the firm’s linkages with universities on innovation and performance.
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Even though university–business alliances have been the topic of some research (Argyres
and Liebeskind, 1998), rarely have they been examined from an entrepreneurial perspective.
Entering these alliances represents an important entrepreneurial act, where managers take
major risks in pursuit of competitive advantage. Alliances are also fraught with technological,
administrative, and financial risks. Organizational-level entrepreneurial activities are usually
characterized by such risks (Lumpkin and Dess, 1996). However, university alliances are an
important way in which firms can obtain, combine, and leverage their resources in innovative
ways that can lead to profitability and growth. These alliances can offset the weaknesses of a
firm’s resources and internal skills. Given that these alliances impact the boundaries of the
firm and determine the sphere of its operations (Williamson, 1985), examining the activities
that influence the domain of the firm is an issue of central interest in the field of
entrepreneurship (Lumpkin and Dess, 1996). Finally, this study explores university–business
alliances in the biotechnology industry. Researchers have noted the importance of this and
other young industries in examining and understanding the entrepreneurial activities of firms
(Zahra and George, 1999; Zucker et al., 1998).
Linkages with universities can enable the firm to gain and master different knowledge
bases that can then be used in developing innovative products to obtain patents that
strengthen its competitive position and financial performance. University–business links
can improve the firm’s innovative outputs and financial performance (Liebeskind et al., 1996;
Peters et al., 1998). In the biotechnology industry, continuous innovation is a strategic priority
in a firm’s efforts to acquire and protect a competitive advantage (Lerner, 1994). Given the
high costs of innovation (Grant, 1998), developing links with universities can be strategically
advantageous for the firms by reducing R&D and other costs.
2.2. University–business linkages as catalyst for alliance formation
Success in new science-based industries requires firms to acquire or develop new and
multifaceted competencies. Competencies are the skills a firm develops by effectively
deploying its diverse assets and resources (Grant, 1998). To succeed, a firm should possess
strong and diverse competencies throughout its operations. These competencies, especially
technology-based, are hard to develop and may take years to assemble (Dodgson, 1992).
Firms can assemble their technological competencies through internal R&D and by using
internal sources that include outsourcing, licensing agreements, and linkages with universities
(Link and Tassey, 1987). This study examines the linkages between biotechnology firms and
universities. These linkages have not been thoroughly examined in prior research (Osborne
and Hagedoorn, 1996).
University–business links are one type of interfirm alliances (Bowie, 1994). Potential
benefits from these alliances include enhanced efficiency, increased profitability (Contractor
and Lorange, 1988), reduced costs (Kogut, 1988), facilitating future technology partnering
(Geisler, 1995; Hagedoorn, 1993), and improving organizational learning (Pennings et al.,
1994). However, some alliances can erode the firm’s competitive advantage and create
complex administrative and coordination problems. They may also raise the firm’s overhead
and other costs, requiring careful management and control systems. Alliances may leak
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information about the firm’s new technologies, allowing competitors to imitate these
innovations quickly. Overall, little is known about the net contributions of university–
business alliances to the firm’s innovative outputs and financial performance.
One problem in studying university–business alliances is the diversity of their objectives
and structures (Eisenberg, 1996), a factor that makes generalizations hazardous (Udell, 1990).
While some alliances are broad-based and are comprehensive relationships that aim at
discovering and commercializing new technologies, others center on licensing agreements
that give a firm access to technology (Trune, 1996). Even when the relationship centers on
licensing some learning occurs. Researchers observe that licensing agreements can give the
firm a greater understanding of how different components interact and how to best assemble
the required technologies. This basic understanding can foster learning that leads some firms
to explore new avenues of research (Sage, 1996). Licensing-based alliances between business
firms and universities, therefore, can improve a firm’s new product development cycle (Hsu
and Bernstein, 1997). Obviously, not all firms can engage in this learning, either because the
licensed technologies fall beyond their areas of expertise or because of their limited ability to
master the new technology. However, firms that learn from their alliances with universities
are positioned to gain superior performance.
Links with established and leading universities can also help to further legitimize the firm’s
operations and increase its access to resources. These links connect the firm to a network of
suppliers, financial institutions, and other companies; some leading universities (e.g.,
Stanford and MIT) typically maintain strong relationships with different firms and stake-
holders (Bowie, 1994). As a firm establishes links with these universities, opportunities for
more linkages (e.g., alliances) with companies in their network increase (Powell et al., 1996).
Given their common link to the same university, these partners are more apt to share their
expertise, knowledge, and resources with the firm, barring the possibility that firms compete
in the same industry (Peters et al., 1998). Even when the firms are competitors, sometimes
they exchange information that supports each other’s growth. In today’s environment,
companies both collaborate and compete with each other (Hamel and Prahalad, 1994).
University–business linkages may also give the firm an opportunity to gain the experience
needed to develop, organize, and manage more alliances (George et al., 2000; Lewis, 1990).
University–business alliances, therefore, can bring together companies that build relation-
ships that subsequently allow the company’s access to the complementary skills they need to
develop and introduce new products. This is especially important where firms do not have
well-developed in-house functional skills, such as marketing and distribution (Zahra, 1996).
Even though university alliances may not strengthen a firm’s technical skills per se, they can
give a company access to complementary skills that improve its performance.
A firm’s absorptive capacity (Cohen and Levinthal, 1990), defined as the ability to
evaluate and assimilate new projects, can determine the success of these alliances. Here too,
linkages with a university can supplement and expand the firm’s absorptive capacity through
learning. As the company learns the skills needed to develop and organize alliances, its
absorptive capacity increases (Zahra and George, 2000). In turn, the company becomes more
proficient in attracting and identifying competent alliance partners, which improves the firm’s
capabilities in developing new products. As absorptive capacity increases, the firm can also
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successfully attract and retain more technology-based alliance partners. Coupled with its
growing experience in evaluating and managing alliances, a firm with links to a university
can attract more and better alliance technology-based partners (Leonard-Barton, 1995). These
observations suggest the following hypothesis:
Hypothesis 1: Firms with university linkages will attract significantly more technology-
based alliances than firms without these linkages.
2.3. University–business linkages and innovative outputs
To succeed in science-based industries, a firm must innovate (Link and Tassey, 1987) and
protect its innovations from imitation by rivals (Grant, 1998). Business–university alliances
can enhance a firm’s innovative outputs, measured by the number of the products created
(Deeds and Hill, 1996; Leonard-Barton, 1995) and the patents achieved (Austin, 1993;
Liebeskind et al., 1996). As noted earlier, linkages with a university can give the firm an
opportunity to enter into alliances with other firms, exposing a company to diverse
management, marketing, managerial, and innovation systems (Leonard-Barton, 1995), a
factor that can increase the firm’s innovativeness (Deeds and Hill, 1996). Aweakness of prior
research is that it does not tell us much about the learning that might occur within business–
university alliances (Oliver and Liebeskind, 1998; Peters et al., 1998). However, frequent
interactions with diverse sources of knowledge also give the firm an opportunity to learn new
skills (Dodgson, 1992). If this is true, then learning from and through alliances and networks
can improve a firm’s ability to develop new products, as found in other studies (Bartmess and
Cerny, 1993; Gulati, 1998). However, the studies just cited have focused on alliances other
than those developed between universities and business firms and used data from established
companies. This study, therefore, seeks to establish if business–university alliances would
yield the same types of results (e.g., higher new products). Confirmation of this effect is
important because we know little about the nature of business–university alliances and how
they may differ in their operations from business-to-business alliances. Yet, differences
between these alliances might arise from the unique cultures of partner academic institutions,
a factor that can affect the management and success of these alliances (Eisenberg, 1996;
Jasso, 1996; Lewis, 1990).
In examining the relationship between university links and new products, however, one
should separate products under development from those that have already been introduced to
the market. Products under development often require a bundle of skills that differ
significantly from those needed for successful commercialization (Afuah, 1998). Biotech-
nology firms usually have several products under development at any point in time, but only a
few of these products eventually reach the market. The arguments presented above would
apply more specifically to products under development. However, empirical evidence is
lacking on the effect of the links companies establish with universities on the number of new
products developed. This study seeks to empirically clarify this relationship.
One way links with universities can increase a firm’s innovative outputs is by giving it
access to valuable resources (Bowie, 1994; Sage, 1996; NSF, 1998). These resources include
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financial, marketing skills or information about market conditions, future partners, and
emerging technological trends. This can help the firm reduce its expenditures and, therefore,
devote more of its funds to support multiple R&D and new product development projects.
Links with universities can also overcome some of the firm’s internal weaknesses in R&D,
while increasing the number of its new products under development (Morris and Hergert,
1987). These observations suggest the following hypothesis:
Hypothesis 2a: Firms with university linkages will have more products under
development than those firms without these linkages.
The process of new product commercialization is usually fraught with risk (Grant, 1998;
Liebeskind et al., 1996), with only a small percentage of products achieving market or
financial success. The greater the number and quality of products under development, the
greater the chances of commercialization. Links to a university can increase the number of
new products that a biotechnology firm eventually introduces to the market and improve the
odds of successful commercialization by providing access to other network members (Peters et
al., 1998). Access to other network members also facilitates the free flow of market-related
and product-related information (George et al., 2000). This enhances the successful commer-
cialization of new products or technologies (Teece et al., 1997) and increases a firm’s market
share (Bell, 1993) and financial performance (Fryxell, 1990). Given the strategic benefits
associated with new product commercialization, a company can capitalize on the learning it
has achieved and the resources it has gained from its links with a university by introducing
more new products to the market. These observations suggest the following hypothesis:
Hypothesis 2b: Firms with university linkages will have significantly more new
products introduced to the market than those firms without such linkages.
Currently, we do not know whether firm–university linkages actually lead to higher rates
of new product development and introductions or not. When a firm succeeds in developing
new product ideas, it is likely to proceed to shield its products from imitation (Zahra, 1996).
Biotechnology companies recognize that competitors have an incentive to quickly copy their
products (Liebeskind et al., 1996). Patents delay imitation (Grant, 1998; Liebeskind et al.,
1996) and serve other strategic purposes such as defending the firm’s market position.
Patents are useful in generating cash flows that support a firm’s R&D and other ongoing
operations through licensing agreements (Afuah, 1998). A firm can also swap its patents to
gain access to other firms’ marketing, distribution, or manufacturing skills. Patents can also
help to preempt rivals’ efforts to flank the firm, protecting the company’s market position
and enhancing its reputation. Investors, customers, and alliance partners also consider patents
when examining their relationships with the firm. Patents are not only a repository of
significant knowledge but they are also an important asset (Zahra, 1996). A firm that owns
significant patents can also determine the speed and direction of the evolution of the industry
(Teece et al., 1997). In the biotechnology industry, where successful product commercial-
ization has been rare, companies have sought to protect their innovations through patents.
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Thus, a biotechnology firm that joins a university alliance has an incentive to patent its
innovations. As the firm becomes more proficient in its innovation and patenting, it can also
learn how to conduct these activities quickly and efficiently, which would increase the total
number of patents the firm obtains. These observations suggest the following hypothesis:
Hypothesis 3: Firms with university linkages will obtain more patents than those firms
without such linkages.
2.4. University–business linkages and cost of R&D
Potential cost reductions are an important reason for a biotechnology firm to forge links
with universities (Geisler, 1995; Kogut, 1988). These links can lower a firm’s overhead costs
by sharing the equipment required for R&D (Lewis, 1990), which is important for those
biotechnology firms that do not have the required funds to maintain extensive R&D facilities
(Geisler et al., 1990). The mutual sharing of information and R&D personnel can also reduce
the firm’s need to invest in R&D. The firm, therefore, can draw heavily on the expertise of the
university’s faculty and graduate students, rather than retaining a large full-time team of
researchers (Geisler, 1995; Lewis, 1990). Universities active in business alliances also
provide several services (e.g., market surveys, prototyping preparation for clinical trials,
and market pretests) that can reduce a firm’s R&D costs. These benefits have been
documented in several UBTI studies (e.g., Allen, 1985; Udell, 1990). For example, the
Virginia Biotechnology Park is closely linked (shared faculty and research resources) to the
Medical College of Virginia, which provides access to experienced medical personnel and
low cost patient testing during trials for the FDA approval process. The center also offers
state-subsidized R&D facilities at lower than market price per square footage, apart from free
consulting and legal advisory services. Finally, Oliver and Liebsekind (1998) observe that
university–business alliances have allowed biotechnology companies to access scientific
knowledge and complementary assets, which would help augment internal R&D.
Sometimes, participation in an alliance with a university can raise the firm’s administrative
overhead. Even though the need to coordinate R&D efforts with those of the university can
increase a firm’s costs, the direct and indirect benefits usually surpass the incremental costs of
coordination, which can lower the firm’s overall R&D costs. Still, despite the potential
benefits and costs associated with university–business links, empirical evidence is lacking.
This paper seeks to establish whether these links in fact reduce R&D costs by testing the
following hypothesis:
Hypothesis 4: Firms with university linkages have lower R&D expenses than those
firms without these linkages.
2.5. University–business linkages and company financial performance
The relationship between university linkages and company performance has been the
subject of some research that has yielded contradictory results (Geisler, 1995). As Udell’s
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(1990) review of past UBTI research would suggest, evidence about these contributions is
inconclusive. UBTI research, however, suggests several reasons why these linkages can
influence a company’s performance adversely. For instance, conflicts between the university
and business cultures can sometimes depress company performance (Cyert and Goodman,
1997). Slow academic bureaucracies may also stifle technology commercialization and
depress the firm’s performance. Links with universities also increase costs because of the
need for coordination, leading to lower performance.
However, business–university linkages can make important contributions to a company’s
financial performance. As noted earlier, universities offer multiple benefits to partner
companies (Mian, 1994, 1997). These benefits can reduce biotechnology companies’
operating costs and improve their performance. These linkages can also facilitate alliances
with other firms, reduce R&D spending, and give the firm access to a pipeline of additional
new products and patents. These products can also build a firm’s reputation, increase its
ability to gain market share, ensure growth, and improve profitability (Buzzell and Gale,
1987; Fryxell, 1990). Patents also give the firm control over its intellectual property and
improve its market standing and reputation (Zahra, 1996). If university links increase the
firm’s ability to obtain patents, then they can improve the firm’s market and financial position
relative to companies without such links.
University–business alliances can also transfer valuable knowledge and technologies that
can spawn innovative products (Burnham, 1997). They also increase a firm’s access to
different knowledge bases that can add to the production of innovative products (Grant,
1996; Kodama, 1995). As alliances multiply, a firm’s absorptive capacity and competence
also rise, allowing the firm to further exploit its knowledge by introducing new products,
gain higher market share (Buzzell and Gale, 1987), and achieve superior value creation
(Zahra and George, 2000). Given these potential benefits, the net contributions of univer-
sity–business linkages on a company’s financial performance are expected to be positive.1
Therefore:
Hypothesis 5: The financial performance of firms with links to universities is
significantly higher than that of firms without such links.
3. Method
To test the above hypotheses, data were collected from the biotechnology industry. This
rapidly growing industry has a strong science-based basic research thrust that requires inputs
from different streams of specialized knowledge (Hamilton, 1996). In 1996, there were 1308
US biotechnology companies producing a wide range of products with applications in human
therapeutics, diagnostics, biomaterials, engineering processes, food preservation, environ-
1 Benefits from alliances, however, may have upper limits. As alliances multiply, companies may reach the
point of diminishing returns because of rising costs of administration and coordination (Deeds and Hill, 1996).
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mental clean up, and veterinary sciences (Biotechnology Industry Organization (BIO), 1996).
The knowledge-intensive nature of the industry has made it an attractive setting for
examining new product development processes (Shan et al. 1994), strategic alliances (Kotabe
and Swan, 1995; Liebeskind et al., 1996; Powell et al., 1996), R&D outsourcing decisions
(Pisano, 1990), innovative output (Austin, 1993), and organizational competence (Henderson
and Cockburn, 1994).
Today, biotechnology is being commercialized in several industries that include
pharmaceuticals, plant and animal agriculture, chemicals, and others (Deeds and Hill,
1998; Shan, 1990). The ‘‘biotechnology industry’’ refers to the manipulation of genetic
material through recombinant DNA technology, cell fusion, and monoclonal antibodies
(Liebeskind et al., 1996). Under this definition, the industry only covers the human
diagnostics and therapeutics segment that is involved in the R&D of drugs or diagnostics
that will be placed in human beings (Deeds and Hill, 1996; Lerner, 1994; Powell et al.,
1996).
Another way to define biotechnology firms is through the system adopted by the US Patent
and Trademark Office (USPTO). Accordingly, Austin (1993) defines a biotechnology patent
as one that has been given the classification number of 930 or 935 by USPTO, which
corresponds to ‘‘peptide or protein sequence’’ and ‘‘genetic engineering: rDNA technology
etc.’’ [CASSIS/ASSIST, 1991 (USPTO index to classification numbers)]. This definition of
biotechnology (patent class no. 930 or 935), which is used in this study, is consistent with
other studies (Deeds and Hill, 1996; Shan, 1990).
3.1. Sample
Two steps were used to identify firms in the sample. In the first, classification through SIC
codes yielded 504 firms — 104 firms in Human Diagnostics (SIC no. 2835), 96 firms in
biological products excluding diagnostics (SIC no. 2836), and 304 in pharmaceutical
preparations (SIC no. 2384). This classification included human therapeutics from biotech-
nology, as well as bulk pharmaceuticals and other specialty drugs. The second step involved
elimination based on a firm’s business focus, as provided in The 1997 GEN Guides to
Biotechnology Companies. Only firms involved in gene therapy, human diagnostics, and
therapeutics were included in the analysis. This process yielded 147 publicly traded firms
with a primary business focus in human gene therapy, diagnostics, and therapeutics. The
number of firms compared favorably with the 474 firms (both public and private firms)
reported by the BIO (1996), and other studies using biotechnology data, including the Shan
et al. (1994) study that used 85 firms and the Deeds and Hill (1996) study that used 132
firms.
3.2. Measures
Data were collected from secondary sources to construct four primary measures: (1)
university linkages, (2) alliance characteristics, (3) R&D investment, and (4) performance.
Alliance characteristics and performance had four submeasures each, as explained below.
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(a) University linkages had the following three submeasures that were included in this
study to highlight the importance of number and quality of these linkages:
1. The sum total of university linkages, a measure previously used in the literature (Arora and
Gambardella, 1994; Deeds and Hill, 1996).
2. The number of Research–I university linkages (Carnegie Foundation, 1996). This measure
was derived from the Carnegie Classification of universities. Accordingly, Research-I
universities were those institutions that are committed to graduate education and placed a
high priority on research. These universities awarded 50 or more doctoral degrees each year
and received US$40 million or more in federal support. It was reasoned that the number of
Research-I linkages that a firm possessed would be indicative of the number of high-quality
research universities with whom the firm interacted.
3. Total federal R&D funding. This measure was used because of its wide acceptance
in academia as an indicator of the quality of ongoing research programs due to the
demanding and prestigious peer-review process of federal funding allocation decisions
(NSF, 1996). Federal funding data for the universities was obtained from the NSF (1996).
The measure was the sum total of federal R&D funding for all the university linkages of an
individual firm.
(b) Alliance characteristics. Consistent with prior research on biotechnology firms, this
study defined an alliance as any cooperative relationship between firms to develop or
commercialize a new product (Deeds and Hill, 1996; Pisano, 1990; Shan et al., 1994). Data
on alliances were obtained from Recombinant Capital, a comprehensive database on
biotechnology firm alliances (Lerner, 1994) recommended by the BIO. The database listed
all the alliances each biotechnology firm had joined since its formation. Thus, all figures for
alliance characteristics are cumulative over the life span of the firm. The database also had
notations on the type (licensing, joint venture, etc.), purpose (business focus), period (number
of years), and size (value in million dollars) of each alliance.
The data collected for the study included all alliances (formal agreements) that the firm has
entered into through the end of 1995. This yielded a total of 2457 alliances (cumulative
count) that were completed by the 147 firms in the sample. Next, these 2457 alliances were
coded to create the following four different submeasures: (a) number of links, (b) type of
linkage, (c) content of the linkage, and (d) knowledge flow, as done previously by Hagedoorn
and Schakenraad (1994). Two coders with graduate academic training in the life sciences
were used to ensure accurate classifications. Coders agreed on their classification of 96.3% of
the alliances. For the remaining 3.7%, a third coder (with a PhD degree in pharmacy) cast the
deciding vote. Data were then used to develop the following four submeasures:
(1) The number of linkages was measured as the total number of alliances, as done
previously in the literature (Arora and Gambardella, 1994; Powell et al., 1996).
(2) The type of linkage was measured by the ratio of the total number of horizontal
linkages to the total number of vertical linkages (Kotabe and Swan, 1995). The log10 value of
the ratio revealed a disposition of the firm to enter different types of alliances. Horizontal
linkages included joint R&D, patent swaps, technology transfers, and joint ventures that
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supplemented a firm’s technology base, whereas vertical links included outsourcing and
distribution links.
Research suggests that the distinction between horizontal and vertical alliances was
necessary because firms gained different benefits from different types of alliances. Horizontal
alliances usually give the firm access to resources (Kotabe and Swan, 1995), especially
knowledge (Bowie, 1994; Lewis, 1990), that expedited new product development, enhanced
the innovativeness of these products, and reduced their development costs (Burnham, 1997).
Vertical alliances also reduced the firm’s costs through efficient outsourcing. However, they
may decrease a company’s expertise in the outsourced applications over time. We acknow-
ledge, therefore, that despite their conceptual distinctiveness, sometimes vertical and hori-
zontal linkages may give a firm more or less the same benefits, depending on the organization
and management of the alliance. One weakness of our study and prior research in this area,
therefore, is that it did not consider how these alliances are organized and managed.
(3) Content of the linkage was measured by the technology-to-market alliance ratio. It was
defined as the log10 of the ratio between the number of R&D-related linkages and the number
of its market-related linkages (Hagedoorn and Schakenraad, 1994). This measure reflected a
firm’s level of technology inclination and attraction, relative to its interest in marketing skills.
By taking the log10 form, equal weights for technology and market links were assumed. A
neutral or zero score, therefore, indicated an equal weight for technology and market links,
whereas a positive score showed an inclination for a technology-oriented link.
Technological and marketing alliances usually give the firm access to different but
complementary types of knowledge (Contractor and Lorange, 1988). While the value of
marketing skills and knowledge for success cannot be overstated, the knowledge embedded in
a firm’s technology (products) is important (Grant, 1998; Teece et al., 1997), especially in
science-based industries, where companies need diverse skills and technologies to achieve
success. While technology alliances are critical for generating new products or supporting
R&D, marketing alliances enable the firm to successfully commercialize such technological
advances (Hagedoorn and Schakenraad, 1994). A successful portfolio of technology and
marketing-based alliances would therefore have important implications for the success of
biotechnology ventures.
(4) Knowledge flow, which was measured by the log10 value of the ratio between the
number of ‘‘generative’’ linkages and the number of ‘‘attractive’’ linkages, indicated the
direction of the knowledge flow (Hagedoorn and Schakenraad, 1994). Generative linkages
were collaborative in nature, involving joint R&D with other firms or universities. Attrac-
tive alliances involved purchasing and licensing agreements. Generative linkages, which
supplied new technology to the firm, were useful in shortening the learning cycle, expediting
product development, and reducing R&D costs. These variables can improve company
performance (Heuss and Jolly, 1991). These linkages also deepen the firm’s mastery of
multiple technologies, which is conducive to developing and introducing highly innova-
tive products that are marketed at premium prices and, therefore, can improve company
performance.
Attractive alliance linkages, which usually conjoin the technological developments started
by several firms, can also enhance a company’s performance. A firm can use these linkages to
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change its products attributes and offer radically new products that are hard for competitors to
copy. These innovative products improve the firm’s profit margins and overall performance
(Buzzell and Gale, 1987). Alternatively, a firm can leapfrog the competition using the
knowledge gained from these linkages. Firms that succeed in applying this strategy are
usually well positioned to set the rules of competitive rivalry and enjoy superior performance
(D’Aveni, 1994). A firm can also exploit its learning by ‘‘fusing’’ different technologies
(Kodama, 1995), combining them in a way that serves new segments where the company can
maintain its technological and market leadership and achieve high performance2 (Link and
Tassey, 1987).
(c) R&D investment was measured in two ways. The first was absolute value of R&D
spending in millions. The second measure was the ratio of a company’s total spending on
R&D (in million dollars) to the total number of full-time employees, thereby adjusting the
R&D spending by company size.
(d) Company performance. The measurement of company performance and the outcomes
of firm–university linkages have been the subject of considerable debate (Burnham, 1997;
Cyert and Goodman, 1997; Harmon et al., 1997; MacLachlan, 1995). Given the complexity
of this construct, four different measures were used in this study. Three of these measures
covered the firm’s innovative outputs, whereas the fourth captured financial performance, as
described below:
(a) The number of patents issued to the firm under USPTO Class 930 or 935 was used as a
key indicator of an innovative output (Austin, 1993). Despite their shortcomings as a
measure of innovation (Grant and Baden-Fuller, 1995), patents captured some of a firm’s
technological knowledge (Almeida, 1996; Liebeskind et al., 1996). Patents were also
highly valued by some of the firm’s stakeholders (e.g., suppliers and venture capitalists),
because they showed progress in a firm’s effort to create new knowledge that one day
might result in new goods (or products). Even though not all the knowledge contained in
patents yielded new products, some of these patents became a source of revenue when
other firms licensed or purchased them. Patents also signalled technological progress by
the firm (Grant, 1996).
(b) The number of products in the market gauged the success of firms in developing and
introducing new products. This measure was among the most widely used indicators of the
firm’s innovative outputs (Cyert and Goodman, 1997; Deeds and Hill, 1996; Harmon et al.,
1997; MacLachlan, 1995).
(c) The number of products under development (in preclinical, clinical, FDA approval
stages) was used as a third indicator of innovative output and, in general, company
performance. It reflected the stock of knowledge-in-progress, which showed a firm’s
ability to sustain its innovative efforts (Lewis, 1990). These products were viewed as the
2 Firms pursue generative and attractive alliances at the same time. Cohen and Levinthal (1990) point out that
a firm cannot generate new knowledge unless it understands the domain of existing knowledge. However, in this
study we use a ratio of generative-to-attractive linkages, which helps us avoid the problems resulting from the
overlapping between the two measures.
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forerunners of a company’s future market offerings, and key stakeholders were likely to
weigh this variable heavily in determining the company’s viability. This measure, which
corresponded to Cyert and Goodman’s (1997) ‘‘intermediate outcomes’’ of firm–
university linkages, was used in evaluating the contributions of these linkages
(MacLachlan, 1995).
(d) Net sales to total assets was employed as a measure of a company’s financial
performance. This measure, which showed the firm’s ability to generate sales with existing
assets, accounted for the sales relative to company size (Wu and Ho, 1997). This ratio was
especially important given a firm’s need to generate the cash flow to support future R&D.
Obviously, this measure has limitations because it can artificially inflate the rate of sales to
assets; many young companies would have limited assets. However, since all firms in the
sample are publicly traded firms, there were no anomalies with regard to either numerator
or denominator being very low thereby skewing the data.
The data for net sales to total assets and R&D spending were collected from Compact
Disclosure and were for 1996 only. The figures for the number of products on the market and
under development, which came from The 1997 Guides to Biotechnology Companies, were
cumulative over the firm’s life span and up to the end of 1995.
4. Analysis
Table 1 presents the means, standard deviations, and interrelations for the study’s variables.
The correlations indicated that as the number of university alliances increased, firms with
these links were able to attract more technology-based alliances with other business firms. As
the number of university alliances increased, firms pursued more ‘‘attractive,’’ rather than
‘‘generative,’’ alliances. Firms also entered into more technology-based alliances than
marketing alliances. Furthermore, there was a modest positive association (P< .10) between
the number of university links and the number of products under development. The
association between the number of university links and patents was not significant. However,
the quality of universities (Carnegie Research-I ties and Federal R&D funding for the
university) with which the firms interacted was significantly correlated with company
performance, products on the market and products under development.
Multivariate analysis of covariance (MANCOVA) was used to test the study’s hypotheses.
In this analysis, the university link was treated as the independent variable. MANCOVA made
it possible to simultaneously consider multiple dependent variables, thereby accounting for
their intercorrelations. Two analyses of covariance (ANCOVAs) were also performed. In the
first analysis, the dependent variables included the four performance measures, R&D
spending, and total number of links. Firm age and size were entered as covariates.
The second ANCOVA included alliance type, content, and knowledge flow along with the
performance measures. This test also attempted to control for university and firm internal
competencies. This analysis included firm R&D spending, the number of Research-I link-
ages, total Federal R&D funding for the universities with which the firm has linkages, and the
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Table 1
Descriptive statistics and correlations (N= 147)
Variables Mean(S.D.) 1 2 3 4 5 6 7 8 9 10 11 12 13 14
(1) Net sales/assets 0.40(0.61) 1
(2) Products in market 1.17(2.19) .34* * 1
(3) Products under
development
3.43(2.35)  .16y .15y 1
(4) Number of
university linkages
1.94
(2.35)
 .18 *  .12 .16y 1
(5) Number of links
(alliances)
17.06
(20.21)
.32* * .32* * .38* * .25* * 1
(6) Type of linkage,
log (horizontal/vertical)
 0.24
(0.37)
 .14  .32* *  .03 .01  .10 1
(7) Content of linkage,
log (technology/
marketing)
0.52
(0.37)
 .26* *  .21 * .12 .38* * .07 .13 1
(8) Knowledge flow,
log (generative/
attractive)
0.03
(0.35)
 .02  .15y  .06  .18 *  .15y .36* * .01 1
(9) Patents
(Class 930 and 935)
3.21
(10.49)
.09 .31* * .43* * .12 .51* * .01  .02  .03 1
(10) R&D spending
per employee
(million dollars)
146.91
(205.68)
 .23* *  .15y  .02  .05  .19 * .02 .05 .06 0 1
(11) Assets
(million dollars)
987.26
(3499.4)
.18 * .57** * .18y  .06 .78** *  .03  .14 .15y .43* *  .17y 1
(12) Age (years) 9.63
(3.27)
.14y .34* * .25* *  .02 .20 *  .28* *  .24* * 0 .35* *  .11 .03 1
(13) No. of
Research-I links
1.31
(1.83)
 .20 *  .18y .16y .93** * .16y .00 .36** *  .14y .04  .04  .16y  .03 1
(14) Federal R&D
fund (million dollars)
235.3
(351.7)
 .17 *  .15y .20 * .87** * .16y  .06 .36* *  .12 .11  .06  .15y .00 .94 * 1
* P < .05.
** P < .01.
*** P < .001.
y P < .10.
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Table 2
Presence of university linkages and its effects on firm performance and alliance attributes
(a) ANCOVA and MANCOVA results of university linkages effects on performance (with total number of
alliances as dependent variable, N= 147)
Dependent variables
Variables Net sales/
assets
Patents Products
(market)
Products
(development)
Total
alliances
R&D
spending
Covariates
Age (years) 0.02* * 1.14** * 0.16* * 0.16* * 1.01** * 1.65* *
Size (assets) 0.00009* * 0.003** * 0.001* * 0.0004* * 0.004** * 0.12** *
Factor
University link
(absent = 0, present = 1)
 0.06  3.6 * 0.69y  0.22 9.19** *  7.92y
Adjusted R2
(overall effect)
0.12** * 0.31** * 0.41** * 0.10 * 0.38** * 0.96** *
Net effects of
test variable
Hotelling’s
trace
Wilk’s l Pillai’s
trace
F statistic
University linkage 0.26 0.80 0.20 4.14** *
(b) ANCOVA and MANCOVA results of university linkage effects on performance (with alliance characteristics
as dependent variables, N = 147)
Dependent variables
Variables Net sales/
assets
Patents Products
(market)
Products
(development)
Type Content Flow
Covariates
Age (years) 0.02 * 0.47* * 0.15** * 0.09  0.02 *  0.04** * 0.001
Size (assets) 0.001 0.002** * 0.003** * 0.003 *  0.0006* * 0.0002  0.0001
R&D spending
(million dollars)
0.004 0.19** *  1.69y 0.03* * 0.005* * 0.0007 0.0006
No. Research-I
universities
 0.09 *  2.28 *  0.28 0.08 0.11y  0.03  0.09
Total Federal
R&D funding
(million dollars)
0.003 0.01 * 0.0005 0.0007 0.0006 * 0.0002 0.0002
Total number of
links (alliances)
0.002 0.29** * 0.04 0.02  0.008y 0.01* *  0.002
Factor
University link
(absent = 0, present = 1)
 0.17 *  0.57 0.45 0.81  0.19 *  0.14y  0.19 *
Adjusted R2
(overall effect)
0.17** * 0.70** * 0.47** * 0.26** * 0.23** * 0.32** * 0.10
Net effects of
test variable
Hotelling’s
trace
Wilk’s l Pillai’s
trace
F statistic
University linkage 0.19 0.84 0.16 2.41 *
* P < .05.
* * P< .01.
** * P < .001
y P < .10.
G. George et al. / Journal of Business Venturing 17 (2002) 577–609 595
total number of alliances along with age and size as covariates. By doing so, we were able to
identify the significance of university linkages after controlling for the firm’s as well as the
university’s competence. Once it was determined that overall MANCOVA was statistically
significant, t tests were used to test 1 Hypotheses 2a Hypotheses 2b Hypotheses 3 Hypotheses
4 Hypotheses 5 by comparing firms with and without university ties (presence of linkage = 1,
absent = 0) in alliance characteristics, R&D spending, number of new products, patents, and
financial performance.
5. Results
5.1. MANCOVA results
Treating university links as the independent variable with company age and size as
covariates, MANCOVAwas significant (F= 4.14, P < .001), with Wilks’ lambda (l) of 0.80,
Pillai’s trace of 0.20, and Hotelling’s trace of 0.26. The results, displayed in Table 2a, also
showed that company age and size were statistically significant across the dependent
variables. The presence of university linkages was significant for the number of alliances
and patents (at P< .05 or better) and marginally significant for two more dependent variables
(products on the market and R&D spending) at P< .10.
A second MANCOVA test (Table 2b) indicated that the presence of university linkages had
an overall effect across the multiple dependent variables examined. MANCOVA was
significant (F= 2.41, P < .05), with Wilks’ lambda (l) of 0.84, Pillai’s trace of 0.16, and
Hotelling’s trace of 0.19. When we controlled for firm and university internal competencies,
the presence of university linkages was significant for three dependent variables (net sales/
assets, type of linkage, and knowledge flow), at P < .05. The test was also marginally
significant for alliance content (P< .10).
5.2. Hypothesis 1
As Table 3 shows, the results of the t tests support the study’s first hypothesis. Firms with
university linkages reported significantly more technology alliances than companies without
such links. Also, firms with and without university links did not differ significantly in the
ratios of horizontal to vertical or generative to attractive alliances. However, firms with
university links had a marginally significantly (P < .10) higher number of alliances than firms
without university links.
5.3. Hypothesis 2
This hypothesis suggested that firms with university linkages will have significantly more
new products under development (Hypothesis 2a) and products on the markets (Hypothesis
2b) than firms without these links. Table 3 shows that there were no significant differences
among firms with vs. without university links in products either under development or on the
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market. Though ANCOVA results (Table 2a) indicate some support at the P< .10 level, the
results do not hold when the analysis controlled for firm and university competencies (Table
2b). However, correlations between number of Research-I linkages and Federal R&D funding
to the dependent variables (Table 1) indicate that the quality of linkages could be more
important to firm performance outcomes, rather than the mere presence or absence of a
university link.
5.4. Hypothesis 3
Biotechnology firms with university linkages were expected to obtain more patents than
firms without such linkages. The t test results supported Hypothesis 3, showing that firms
with links to universities had significantly more patents than firms without these links
(P< .05).
5.5. Hypothesis 4
Firms with university linkages were expected to have lower R&D expenses than firms
without university linkages. The results supported Hypothesis 4, showing that firms with
university linkages spent less (per employee) on R&D than firms without these linkages
(P< .01).
Table 3
Differences in alliances, innovative outputs, and performance: companies with vs. companies without univer-
sity links
Variables Companies
with links to
universities
Companies
without links
to universities
Mean
difference
t value
Total number of links 19.35a (18.27)b 12.69 (23.33) 6.66 1.87y
Log technology/marketing
alliances
0.60 (0.37) 0.34 (0.32) 0.26 4.03** *
Log horizontal/vertical
alliances
 0.22 (0.38)  0.28 (0.34) 0.06 0.88
Log generative/attractive
alliances
0.04 (0.37) 0.02 (0.32) 0.02 0.24
Products under development 3.53 (2.31) 3.19 (2.55) 0.34 0.69
Products on the market 1.04 (2.14) 1.50 (2.37)  0.46 1.54
Patents 4.68 (12.84) 0.60 (1.32) 4.08 2.24 *
R&D spending 131.24 (113.03) 180.48 (319.60)  49.24 7.53* *
Net sales/total assets 0.32 (0.34) 0.44 (0.61)  0.12  1.52
a Means.
b Standard deviations.
* P< .05.
* * P< .01.
** * P < .001.
y P < .10.
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5.6. Hypothesis 5
This hypothesis suggested that the financial performance of firms with university linkages
will be higher than for those firms without such links. There was no statistically significant
difference among the firms when the ratio of net sales-to-total assets was considered.
However, ANCOVA results (Table 2b), when controlled for firm and university competence,
indicated a statistically significant effect of university linkage on firm performance. Also, the
number of high-quality university linkages measured by the number of Carnegie Research-I
linkages has a significant effect on performance (P< .05).
6. Discussion
The benefits a business firm might gain from establishing links with universities have been
the subject of interest in the literature (Cyert and Goodman, 1997; Eisenberg, 1996; Sage,
1996). Despite their growing popularity, the contributions of these linkages to the innovative
outputs and performance of business companies have not been well documented. This study
sought to fill this gap in the literature. The results of the study are summarized and discussed
below.
6.1. Hypothesis 1
Results from Hypothesis 1 show that firms with university linkages enter into more
business alliances than firms without such links. Perhaps these links serve as a magnet that
draws technology alliance partners to join alliances with other firms. These technology
alliances can improve the firm’s knowledge base and competence, which can increase a firm’s
chances of survival. These alliances can give the firm access to emerging technologies that
can be used to upgrade existing skills or venture into new fields, thus setting the stage for
future growth and profitability (Teece et al., 1997).
But why do firms with university links develop more alliances than firms without these
links? Given the nature of the data, we can only speculate that firms that develop these linksmay
bemore technologically proficient in their industry and, therefore, attract additional alliances. It
is also possible that biotechnology firms continue to struggle with the accumulation of their
technological competencies, and therefore may not pursue marketing alliances as vigorously.
Of course, the results might reflect the current stage of the biotechnology industry’s life cycle,
where emphasis centers on creating products. As the industry becomes more established,
attention will shift to gaining marketing competencies through alliances with other firms and
universities. These possibilities should be examined in future empirical research.
6.2. Hypothesis 2
The number of university linkages is marginally associated (r=.16, P< .10) with products
under development but not with products on the market. This suggests that university
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linkages can help some biotechnology firms emerge from an incubator stage by attracting
technology and getting more products into development. However, the more powerful
statistical tests performed on this hypothesis did not support these findings. Since ANCOVA
considers the presence (or absence) of university linkages rather than the absolute number of
university linkages, some of the university linkages may be critical to product development,
while others may serve to bring in new knowledge that may not directly translate into
products under development.
The results do not show a relationship between products on the market and number of
university linkages, probably because the drug development process is lengthy, complex, and
has several stages (Liebeskind et al., 1996), and the chances that any product that is in
preliminary research will reach the market is about 1 in 1000 (BIO, 1996). With such a small
product success rate, there is less chance of obtaining a statistically significant association
between university linkages and the biotechnology products introduced to the market.
Biotechnology firms, in general, have not been successful in commercializing their new
products (BIO, 1996). Also, as firms come close to developing a product, they are likely to
distance themselves from universities to increase appropriability and reduce royalty payments
(Recombinant Capital, 1996). The results also highlight the importance of quality of the
university with whom the firm interacts. There is a significant correlation between the
university’s Federal R&D funding and the products under development. But the correlation
coefficient turns negative with products on the market (at P< .10), thereby supporting our
earlier discussion of appropriability concerns.
6.3. Hypotheses 3 and 4
The hypothesized relationships with the number of patents or innovativeness (Hypothesis
3) and R&D cost savings (Hypothesis 4) are supported. The results show that firms with
university ties have significantly more patents and spend a significantly lower amount on
R&D spending than firms without these linkages. These combined efficiencies may arise
from cost sharing in equipment (Lewis, 1990), pooling of scientific talent, and sharing of
information through social networks (Bowie, 1994; Liebeskind et al., 1996; Oliver and
Liebeskind, 1998), especially where knowledge is more likely to be tacit (Cohen and
Levinthal, 1990). These variables can give a firm significant strategic advantage in cost
efficiencies and competitive positioning. Noteworthy are the significant effects of the quality
of university ties on innovative output (Table 2b). The number of research university ties and
the Federal R&D funding are indicative of the quality of the firm’s linkages in its ability to
attract useful, innovative knowledge.
The above results support the strategic importance of developing links between business
firms and universities. Firms that develop these links have significantly higher numbers of
patents, which are a major source of market value in the industry (Zahra, 1996). Furthermore,
given the youth of the biotechnology industry, patents represent a milestone in a firm’s quest
for building a technology-based alliance. Patents are also important indicators of the
accumulation of knowledge, which is a prerequisite to future successful product development
and commercialization (Almeida, 1996; Grant and Baden-Fuller, 1995).
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The finding that firms with university links have lower R&D spending than firms
without these links suggest multiple interpretations. For example, firms with such links
have a lower base of R&D spending than firms without these links. Consequently, firms
with lower R&D spending will be motivated to enter university alliances to defray
overhead and other administrative costs. Alternatively, university links may offer advan-
tages to participating firms, thereby lowering R&D costs. These rival explanations should
be considered in future studies to determine the ways in which business–university
alliances effectively reduce the firm’s R&D spending. For the time being, however, the
results show that biotechnology firms with university links report lower R&D spending
than those without such links.
From a managerial perspective, the fact that there are significant differences in new
products and patents between firms with linkages with universities and those without those
linkages is interesting. If the firm’s strategy centers on increasing innovation, then establish-
ing linkages with universities is one approach to reach this goal. Product innovation is widely
viewed as an important strategic priority in the biotechnology industry (Zahra, 1996).
Another way a firm can leverage the benefits it gains from these linkages is to use patents
to enter into other alliances with firms in the industry (Teece et al., 1997) or simply license its
technologies. The firm may also use patents defensively and preempt competitors from entry.
Finally, the finding that firms with links report lower R&D spending has some strategic
implications. Given that the cost of R&D is one of the key components of the firm’s pricing
structure, lower R&D costs can be used to lower prices and build the firm’s market share.
Lower R&D costs can allow the firm to focus on supporting the development of other
functional skills, such as operations and marketing.
6.4. Hypothesis 5
The data do not support the performance effects of university linkages. Contrary to
expectations, the results show that firms with university ties do not have any significantly
higher net sales-to-assets ratio than biotechnology companies without these links. However,
given the nature of the secondary data used in this research, it is possible that companies
with strong financial track records do not seek alliances with universities. Firms seeking
such ties with universities may be offsprings of university-based scientific talent. Indeed, it
is not uncommon to see scientists and professors leave university employment to start their
own firms when a chemical compound or genetic strain has been isolated (Roberts, 1991).
However, scientists prefer to maintain university ties to share ongoing research results as
well as maintain access to the scientific knowledge pool (Audretsch and Stephan, 1996).
These fledgling firms are likely to be located in research parks and have virtually no sales,
other having a lower sales-to-assets ratio than independent ventures with established
product lines. Our study did not distinguish between firms based on locational factors
(Audretsch and Stephan, 1996) or participation in a research park or incubator (Mian, 1994,
1996), which should be examined in future research. Given that the study’s performance
measure was lagged by only 1 year, future researchers should consider a longer time frame
in establishing the effect of university linkages on company financial performance. It is
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possible that university linkages improve company financial performance but these
improvements might not have materialized in the current sample because of the study’s
short time frame.
One of the study’s surprising findings is that the hypotheses for the performance variables
(products under development, products on the market, and financial performance) were not
supported, whereas the hypotheses on intermediate outcomes were supported. As we have
just noted, the short time lag related to performance variables might account for this.
Companies might have gained the skills to develop new products, but have not yet mastered
the skills associated with marketing them and making a profit. As stated earlier, commerci-
alization remains a major problem facing many biotechnology companies. It is also possible
that firms are making sacrifices in the short term hoping to cash in on their discoveries later.
Alternatively, companies in the sample are investing heavily in managing their alliances by
devoting money for administrative overhead while investing less in their R&D, whereas their
counterparts without university links may not have to make these tradeoffs. These explan-
ations require further analysis in future research.
6.5. Limitations
The findings on increased innovative activity combined with a reduction in R&D costs are
preliminary and should be interpreted with caution because of the study’s shortcomings. The
study’s cross-sectional design makes it difficult to establish casual relationships among the
variables. Further, although the Carnegie classification and Federal funding measured the
quality of firm–university linkages, the study did not measure the quality and nature of
interactions between the firm and the university. The quality of the linkages, however, can
spell the difference between success and failure in knowledge transfer and utilization (Arora
and Gambardella, 1994; Oliver and Liebeskind, 1998) or attaining competitive advantage
(Harmon et al., 1997). Also, while there are several important benefits for single industry
studies, the fact that this research was conducted in the biotechnology industry might limit the
generalizability of findings to other industries or even other sectors of the industry.
Another limitation of this study is the exclusion of privately held firms and those firms that
belong to a university incubator or research park system. By excluding these firms, we have
narrowed the scope of the important payoffs of university linkages. Many high-technology
spin-offs reside in these parks but remain privately held, a factor which makes access to
alliance or performance data difficult. Mian (1997) identifies several potential problems in
this regard, including selection bias, lack of control variables, and poor data sources. Though
university incubators are an important source for technology-based entrepreneurship (Rob-
erts, 1991), data availability clearly restricted the scope of our study. Also, given the dynamic
evolution of the biotechnology industry, the results might capture relationships among
variables of interest at only one point in time. The study did not explore the differences in
firms’ ability to manage their university alliances and how these differences might affect a
company’s innovative and financial performance. Companies need to develop those skills that
will enable them to manage these alliances effectively, and the current study did not examine
this issue. Finally, the study did not consider firms’ motives for entering into linkages with
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universities; these goals can determine the outcomes of these linkages. The secondary data
used did not allow us to distinguish different types of linkages. Still, the results have several
implications for effective managerial practice and future research.
6.6. Implications for managerial practice
One key message from this study is that linkages with universities are positively associated
with a firm’s innovative outputs. Given the crucial value of innovation for survival in the
biotechnology industry, these preliminary results suggest that some business firms can benefit
from developing and effectively managing linkages with universities. While these relation-
ships can be costly and challenging, they can be strategically valuable in terms of the firm’s
innovative outputs.
Though the number of high-quality university linkages influences innovative output, there
are no guarantees that these benefits will materialize. Therefore, managers need to evaluate
the risks and rewards of linkages with universities by examining the skills and capabilities
they might bring to the alliance. This can be achieved by considering the composition and
capabilities of the faculty and staff, institutional culture and bureaucracy, prior experiences
with other business firms, available research space and equipment, and the importance the
university attaches to its linkage with the company. Companies should also evaluate these
variables as they determine whether or not to formalize these links. In evaluating the merits of
these alliances, however, executives need to recognize their importance in connecting the firm
with other companies in pursuit of innovation, as indicated by the increased number of
patents the firm might obtain.
Managers should be aware that linkages with universities may not positively impact their
companies’ short-term performance. Indeed, these linkages are not significantly associated
with short-term financial performance. The costs associated with managing these alliances
and the possible tradeoffs between covering the costs of managing alliances, while reducing
R&D costs, are potential explanations of the insignificant results observed here. These results
highlight the need for managers to carefully evaluate the contributions of linkages with
universities, realizing that they may not pay off in the short term.
6.7. Implications for future research
The results also suggest several issues to be considered in future studies. One area for
future research is to examine biotechnology firms which are members of UBTIs or research
parks and are not publicly traded. Future research should establish whether or not the results
reported in the current paper apply to them. As stated earlier, publicly traded firms may
pursue goals that differ from those achieved by firms that are not traded publicly.
There is a need to examine the nature, quality and duration of firm–university linkages in
theorizing about their effect on a firm’s innovative outputs and financial performance.
Universities may structure their relationships differently with different firms (ranging from
collaborative R&D to patent licensing), a factor which suggests that the attributes of this
relationship can significantly impact its results. Accounting for, and incorporating, these
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attributes can therefore enrich future theory building and provide a solid empirical basis to
assess the results of firm–university linkages.
Another issue is why some firm–university linkages are successful and others are not. The
attributes, context, and management of these relationships can determine whether or not they
succeed in improving a company’s innovative outputs and financial performance (Cyert and
Goodman, 1997). Researchers, therefore, need to study these key variables and establish their
relative contributions to the results of firm–university relationships, measured by innovative
outputs and financial performance.
The dynamic nature of the relationships between the variables examined in this paper
should be explored in future studies. Absorptive capacity and new product development, for
example, are path-dependent activities (Cohen and Levinthal, 1990; Zahra and George,
2000), where future success depends on the firm’s past achievements. The dynamism of
science-based industries, along with the path-dependent relationships just noted, suggests a
need for longitudinal research designs that permit the application of causal modeling
techniques to establish the direction and strength of the relationships among the study’s
variables.
As noted previously, our knowledge of the differences in scope, goals, operations, and
management of university–business alliances is limited. Therefore, we were compelled to
rely heavily on prior findings from research on business-to-business alliances. To move the
literature forward, we need studies that compare these two different types of alliances and
establish where they are different and where they are similar. These studies would help to
clarify when and how university–business alliances create competitive advantages for
participating firms. Toward this end, it would be useful to gauge the objectives of both
firms and universities from developing these linkages.
Another area that deserves attention in future research is the effect of university–business
alliances on a company’s performance. Individual measures of financial performance have
serious weaknesses, and the use of multiple measures can provide a more realistic view of the
effect of alliances on the multiple indicators of company performance. Therefore, we would
like to encourage future researchers to consider multiple financial measures to establish the
efficacy of these alliances. Longitudinal designs would further improve our appreciation of
the contributions of these alliances to companies’ performance over time.
The formation and payoff from alliances, including those developed between univer-
sities and firms, can be explained using a variety of perspectives (Contractor and Lorange,
1988). In this paper, we relied heavily on the strategic choice perspective. To better
explain the formation of these alliances, future researchers need to consider and integrate
multiple perspectives (Osborne and Hagedoorn, 1996). Such integration can help to
explain how alliances (particularly the linkages created by universities and business firms)
enhance performance. For example, the use of the legitimacy and institutional perspectives
can help to show why these linkages come into existence in the first place. The strategic
perspective can clarify the reasons why linkages are structured differently and the
conditions under which they can add value to the firm’s innovative and financial
performance. The learning perspective can explain the various types of knowledge to
be gained from these linkages.
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Business firms and universities are under considerable pressure to cooperate by joining
forces and developing alliances beneficial to both parties. Universities are under pressure
from the general public to become more involved in the lives of their communities. Students
are also pressuring universities to provide them with opportunities to hone their skills.
Businesses are under mounting pressure because of the intense competitive conditions in their
industries. Competitors are becoming more and more agile and innovative. Customers are
more demanding and products are growing in complexity. These pressures have served to
bring more and more universities and business firms into collaborative linkages. This is
especially the case in science-based industries, such as biotechnology, where technological
change is rapid and the need to acquire multiple competencies is great. In an era of limited
resources, these linkages can give universities revenues that allow the vigorous pursuit of
cutting-edge research. Universities and companies can benefit from entering and supporting
such mutually beneficial alliances.
7. Executive summary
In recent years high-technology companies have developed close links with universities.
These links are important for developing and transferring new technology as well as the
creation of new products and goods. Links with business firms are also an important source of
revenues and new knowledge for some universities. Links with leading universities in
particular serve other important purposes, such as improving a firm’s reputation and
increasing its access to key sources of innovation. These links can connect business firms
to sources of information about new scientific discoveries. Though challenging, costly and
time consuming, these links can give the firm important competitive advantages that improve
their markets. Understandably, more and more companies have actively sought to establish
links with universities.
The growing links between universities and businesses have attracted some scholarly
attention. Researchers have examined the organizational and political challenges that
companies and universities face in building mutually beneficial alliances. Researchers have
also studied the obstacles to the effective transfer of technologies developed from these
alliances. Even though this research has enriched our understanding of the contributions of
business–university links, some basic questions remain unanswered. Do these links
improve the business firm’s performance? Do they enhance the firm’s ability to develop
and introduce new products to the market? Do they increase its ability to obtain patents?
How do these links impact a business firm’s spending on R&D? This study seeks to answer
these questions.
Using data from publicly traded biotechnology companies in the US, this study finds that
firms with established links to universities (n = 97) surpass firms without such links (n= 50)
in the number of their patents and had significantly lower R&D spending than firms without
these links. These results indicated that links with universities might serve as a substitute for
expensive in-house R&D spending. While other causes of lower R&D spending are possible,
this interpretation was reinforced by the finding that companies with university links were
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able to attract more technology alliance partners. These links can enhance the firm’s
technological innovations without the need for expensive in-house R&D.
The results also show that, as anticipated, links with universities can enhance product
development and other key indicators of a company’s innovative outputs such as patents.
However, we did not find statistically significant differences in financial performance
(measured by the ratio of net sales to assets) between firms with university linkages and
those without these linkages. Results also indicated that the quality of university linkages
(measured as Carnegie Research-I University and Federal R&D funding for universities)
significantly influence the performance outcomes of these alliances. Given the complex
organizational and operational issues that arise in the course of developing and managing
university and business alliances, managers need to study the merits and limitations of these
linkages. Managers should not simply follow other companies seeking these linkages;
instead, they should evaluate potential partners and develop the structure that best suits their
firm’s situation. Linkages with universities are costly because they can raise administrative
overhead. Success in these linkages requires the firm to develop specific managerial and
administrative competencies, which is a time-consuming process. Companies that do not have
these skills may not fully gain the benefits associated with these linkages. Indeed, companies
can benefit from these links by gaining significant strategic advantages, especially in terms of
innovative outputs. These results should be interpreted and used with caution because our
analyses focused on publicly traded biotechnology companies that were not members of
university incubators or research parks and, therefore, may not apply to privately held firms.
Clearly, our results indicate that links with universities (especially those with a strong
research mission) can be strategically beneficial to publicly traded biotechnology companies.
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